Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RNU2-3P gene (RNA, U2 small nuclear 3, pseudogene) is a human pseudogene related to the U2 small nuclear RNA family. Unlike the functional U2 snRNA, which is a core component of the spliceosome and essential for intron removal in pre-mRNA splicing[1], RNU2-3P does not encode a functional product and has no recognized biological activity. It is annotated as a pseudogene in genomic databases and is not known to contribute to disease, interact with drugs, or act as a biomarker. Alternative names include U2, RNU2P1, and RNA, U2 small nuclear pseudogene 1[5][2][3]. No evidence supports its use as a therapeutic target or its involvement in any biological or disease processes. It is important to distinguish RNU2-3P—a non-functional pseudogene—from functional U2 snRNA, which does play critical biological roles[1][5][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 3, pseudogene (RNU2-3P).